Hayat Pharmaceutical Industries Co (AMM:HPIC) Research & Development: JOD0.91 Mil (TTM As of Mar. 2026)


AMM:HPIC Hayat Pharmaceutical Industries Co AMM:HPIC
79 GF Score
Price JOD3.13
GF Value JOD2.74
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hayat Pharmaceutical Industries Co Research & Development?

Hayat Pharmaceutical Industries Co AMM:HPIC +0.32% 79 Research & Development is JOD0.91 Mil as of Mar. 2026. GuruFocus rates AMM:HPIC with a GF Score™ of 79/100 and a GF Value™ of JOD2.74 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hayat Pharmaceutical Industries Co's Research & Development for the three months ended in Mar. 2026 was JOD0.25 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was JOD0.91 Mil.

Hayat Pharmaceutical Industries Co  (AMM:HPIC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hayat Pharmaceutical Industries Co Research & Development Related Terms

Hayat Pharmaceutical Industries Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hayat Pharmaceutical Industries Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co Research & Development Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.58 0.66 0.70 0.85

Hayat Pharmaceutical Industries Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.19 0.26 0.21 0.25
AMM:HPIC
79GF Score
Hayat Pharmaceutical Industries Co AMM:HPIC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hayat Pharmaceutical Industries Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD0.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of JOD0.91 Mil mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a Research & Development of JOD0.91 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hayat Pharmaceutical Industries Co and its competitors.
Is Hayat Pharmaceutical Industries Co's Research & Development too high?
Hayat Pharmaceutical Industries Co's current Research & Development is JOD0.91 Mil. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's Research & Development compare to ZTS and UTHR?
Hayat Pharmaceutical Industries Co's Research & Development of JOD0.91 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hayat Pharmaceutical Industries Co and its competitors. Hayat Pharmaceutical Industries Co's current Research & Development is JOD0.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.13 — trading 14.2% above its estimated fair value. The current Research & Development is JOD0.91 Mil. Hayat Pharmaceutical Industries Co's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current Research & Development is JOD0.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?

Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued. The current stock price of JOD3.13 is trading 14.2% above its estimated GF Value™ of JOD2.74. GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.

Key valuation signals for AMM:HPIC:

  • Research & Development: JOD0.91 Mil
  • GF Value™: JOD2.74 vs. price of JOD3.13 (14.2% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hayat Pharmaceutical Industries Co Business Description

Address Mohammed Ali Alkurdi St. Al-Rajeeb Amman, 1564 Amman, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
79GF Score

Get the complete analysis for AMM:HPIC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD3.13
Price
JOD2.74
GF Value